Dermatology
The Evolving Landscape of Alopecia Areata
This is a CFPC Mainpro+ accredited 15-minute expert brief for Canadian primary care providers and other healthcare professionals. The goal is to provide education on the burden of alopecia areata and the evolving landscape of alopecia areata treatment. The expert brief video will feature a conversation between a Dermatologist and a Family Physician.
DURATION
15 Min
PROFESSION
Physician, Pharmacy, Specialist
# OF CREDITS
0.25
ACCREDITATION
Mainpro+
EXPIRY DATE
2024-07-19
Alopecia areata (AA) is a chronic and highly unpredictable autoimmune disorder affecting growing hair follicles in susceptible individuals, which results in non-scarring hair loss and negatively impacts quality of life. Current treatment options include topical and systemic steroids, steroid injections, minoxidil, and topical sensitizers. Emerging research on AA immunopathogenesis shows that local inflammation in AA is largely mediated by the Janus kinase(JAK)/signal transducer and activator of transcription (STAT) pathway; this has led to the rapid development of JAK inhibitors as a breakthrough therapeutic option for AA.
This program has received financial support from Pfizer and ICE-BM in the form of an unrestricted educational grant.
Faculty
Franchesca Cheung, MD, CCFP, FCFP
Jeff Donovan, MD, PhD, FRCPC
Christine Palmay, MD, CCFP, FCFP
Sofia Nastis, MD, CCFP
Learning objectives
Upon completion of this continuing education program, participants will be better able to:
- Describe the burden of disease of alopecia areata.
- Summarize emerging literature on the immunopathogenesis of alopecia areata.
- Discuss the evolving approach to the management of alopecia areata.